Alimera Sciences

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Company Growth (employees)
Type
Public
HQ
Alpharetta, US
Founded
2003
Size (employees)
125 (est)
Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US

Key People at Alimera Sciences

Ken Greene

Ken Greene

CSO
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman

Philip Ashman

SVP & European Managing Director
Rick Eiswirth

Rick Eiswirth

President & CFO
Dave Holland

Dave Holland

SVP of Sales & Marketing

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Lisbon and Hampshire
Alpharetta, US (HQ)
6120 Windward Pkwy
Hampshire, GB
Wellesley Rd
Berlin, DE
21 Cicerostraße

Alimera Sciences Data and Metrics

Alimera Sciences Financial Metrics

Alimera Sciences's revenue was reported to be $34.3 m in FY, 2016 which is a 53% increase from the previous period.
USD

Revenue (FY, 2016)

34.3 m

Revenue growth (FY, 2015 - FY, 2016), %

53%

Net income (FY, 2016)

(33.2 m)

EBIT (FY, 2016)

(27.8 m)

Market capitalization (28-Jun-2017)

87.6 m

Closing share price (28-Jun-2017)

1.4

Cash (31-Dec-2016)

31 m
Alimera Sciences's current market capitalization is $87.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.9 m8.4 m22.4 m34.3 m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9 m

Gross profit

9 k7 m20.7 m

Gross profit Margin, %

0%83%92%

Operating expense total

34.4 m39.9 m59.7 m

EBIT

(46.2 m)(32.9 m)(39 m)(27.8 m)

EBIT margin, %

(2469%)(391%)(174%)(81%)

Net Income

(46.2 m)(35.9 m)(30.6 m)(33.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.6 m76.7 m31.1 m31 m

Accounts Receivable

500 k850 k9.8 m13.8 m

Inventories

3.5 m3.2 m2.7 m2.1 m

Current Assets

18.6 m83.3 m45.2 m47.4 m

Total Assets

19.6 m109.4 m70.5 m70.2 m

Accounts Payable

1.7 m5 m4 m5 m

Current Liabilities

4.9 m10.5 m39.9 m9.1 m

Additional Paid-in Capital

240.1 m292.9 m299.4 m330.8 m

Retained Earnings

(277.3 m)(313.3 m)(343.9 m)(377.1 m)

Total Equity

26.3 m25.6 m

Financial Leverage

2.7 x2.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.2 m)(35.9 m)(30.6 m)(33.2 m)

Depreciation and Amortization

138 k659 k2.6 m2.8 m

Accounts Receivable

(483 k)(444 k)(8.9 m)(4.1 m)

Inventories

(1.4 m)206 k405 k556 k

Accounts Payable

(259 k)3 m(487 k)1.1 m

Cash From Operating Activities

(37.8 m)(24.3 m)(45.4 m)(25.1 m)

Purchases of PP&E

(973 k)(842 k)(451 k)(186 k)

Cash From Investing Activities

(973 k)(25.8 m)(451 k)(186 k)

Cash From Financing Activities

1.7 m114.7 m625 k25.4 m

Interest Paid

607 k1.2 m4.2 m4 m

Income Taxes Paid

263 k193 k
Y, 2016

Financial Leverage

2.7 x

Alimera Sciences Market Value History

Alimera Sciences Online and Social Media Presence

Alimera Sciences Company Life and Culture

You may also be interested in